VYNE Therapeutics Inc. (VYNE) - Dilution Analysis

10-Q filing | 33.4M shares outstanding

10-Q filing | 25.5M shares outstanding

10-Q filing | 16.7M shares outstanding

10-K filing | 15.2M shares outstanding

10-Q filing | 14.8M shares outstanding

10-Q filing | 14.7M shares outstanding

10-Q filing | 14.5M shares outstanding

10-K filing | 14.1M shares outstanding

S-3 filing: VYNE Therapeutics Inc. may offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering, up to $250.0 million of any combination of common stock, preferred stock and warrants.

10-Q filing | 14.0M shares outstanding

S-3 filing: This is an S-3 filing for the proposed resale of up to 39,266,980 shares of common stock by selling stockholders, consisting of shares held by the selling stockholders and shares issuable upon the exercise of outstanding pre-funded warrants.

8-K filing: VYNE Therapeutics Inc. entered into a Securities Purchase Agreement to sell 10,652,543 shares of common stock and pre-funded warrants to purchase 28,614,437 shares at $2.245 per share, expecting gross proceeds of $88.2 million. ($88.2M proceeds)

10-Q filing | 3.3M shares outstanding

10-Q filing | 3.3M shares outstanding

10-K filing | 3.2M shares outstanding

8-K filing: Stock split 1-for-18 | Outstanding: 57,930,000 → 3,251,871

8-K filing: VYNE Therapeutics Inc. redeemed all outstanding shares of its Series A Convertible Preferred Stock for an aggregate of $360,000 and filed a Certificate of Elimination with respect to the Series A Preferred Stock. ($0.36M proceeds)

10-Q filing | 57.9M shares outstanding

10-Q filing | 57.9M shares outstanding

10-Q filing | 55.4M shares outstanding

10-K filing | 51.5M shares outstanding

10-Q filing | 52.0M shares outstanding

10-Q filing | 51.4M shares outstanding

10-Q filing | 51.4M shares outstanding

S-3 filing: VYNE Therapeutics Inc. files an S-3 registration statement for the potential offering of common stock, preferred stock and warrants up to an aggregate amount of $200,000,000.

10-K filing | 51.3M shares outstanding

8-K filing: Stock split 1-for-4 | Outstanding: 167,878,646 → 51,300,000

10-Q filing | 167.9M shares outstanding

10-Q filing | 167.7M shares outstanding

8-K filing: Menlo Therapeutics Inc. completed an offering of 27,050,000 shares of common stock at $1.850 per share, and an additional 4,057,500 shares were sold through the exercise of an underwriter option, resulting in estimated net proceeds of $53.6 million.

10-Q filing | 136.3M shares outstanding

8-K filing: Each contingent stock right (CSR) will be converted into 1.2082 shares of Common Stock, resulting in an effective exchange ratio in the Merger of 1.8006 shares of Common Stock for each Foamix Share, and legacy Foamix shareholders and their transferees will own approximately 82% of the outstanding shares of the Company.

10-K filing | 24.4M shares outstanding